[Prevention and treatment of the "irreducible mydriasis--progressive atrophy of the iris" syndrome following perforating keratoplasty for keratoconus].
D000109:Acetylcholine / Q000627:therapeutic use*; D000779:Anesthetics, Local / Q000627:therapeutic use*; D001284:Atrophy; D001285:Atropine / Q000627:therapeutic use*; D005128:Eye Diseases / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D005131:Eye Injuries / Q000150:complications; D006145:Guanethidine / Q000627:therapeutic use*; D006801:Humans; D007498:Iris; D007640:Keratoconus / Q000601:surgery*; D010656:Phenylephrine / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D011680:Pupil; D012601:Scopolamine / Q000627:therapeutic use*; D013564:Sympathetic Nervous System / Q000503:physiopathology*
D000779:Anesthetics, Local; D010656:Phenylephrine; D001285:Atropine; D012601:Scopolamine; D000109:Acetylcholine; D006145:Guanethidine
Prophylaxie et traitement du syndrome "mydriase irréductible--atrophie irienne progressive" succédant à une kératoplastie perforante pour kératocone.